Skip to main content

Spark 'very encouraged' by gene therapy data, targets 2021 for pivotal study

The company's goal is to produce a hemophilia A gene therapy that demonstrates "safety, predictability, efficacy, and durability."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.